Accepted for/Published in: JMIR Public Health and Surveillance
Date Submitted: Jan 31, 2023
Date Accepted: Apr 19, 2024
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Drug-resistant tuberculosis case-finding strategies: a scoping review
ABSTRACT
Background:
Finding individuals with drug-resistant (DR) tuberculosis (TB) is important to control the pandemic and improve patient clinical outcomes. To our knowledge systematic reviews assessing effectiveness, cost-effectiveness, acceptability, and feasibility of different DR-TB case-finding strategies to inform research, policy, and practice, have not been conducted and the scope of primary research is unknown.
Objective:
We assessed the available literature on DR-TB case-finding strategies using standard scoping review methodology.
Methods:
We looked at systematic reviews, trials, qualitative studies, diagnostic test accuracy studies and other primary research that sought to improve DR-TB case detection specifically. We excluded studies that included patients seeking care for TB symptoms, patients already diagnosed with TB or were laboratory-based. We searched the academic databases of Medline (PubMed), Embase (Ovid), The Cochrane Library, Africa-Wide Information (EBSCOhost), CINAHL (EBSCOhost), Epistemonikos and PROSPERO using no language or date restrictions. We screened titles, abstracts, and full text articles in duplicate. Data extraction and analyses were done in Excel.
Results:
We screened 3,028 titles and abstracts and 177 full-text articles. We identified six systematic reviews and 44 primary studies. Five reviews described yield of contact investigation and focused on household contacts, airline contacts, comparison between drug-susceptible and DR-TB contacts and concordance of DR-TB profiles between index cases and contacts. One review compared universal versus selective drug resistance testing. Primary studies described the following: 26 contact investigations; 11 outbreak investigations; 3 airline contact investigations; 2 epidemiological analyses; 1 public-private partnership programme; and an e-registry programme. Primary studies were all descriptive and included cross-sectional and retrospective reviews of programme data. No trials were identified. Data extraction from contact investigations was difficult due to incomplete reporting of relevant information.
Conclusions:
Existing descriptive reviews can be updated, but there is a dearth of knowledge on the effectiveness, cost-effectiveness, acceptability, and feasibility of DR-TB case-finding strategies to inform policy and practice. There is also a need for standardisation of terminology, design, and reporting of DR-TB case-finding studies. Clinical Trial: NCT05022238
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.